Annexon, Inc. (ANNX): Cash & Equivalents
$162.05M
As of 2025-12-31
$199.27M
As of 2026-06-30
+5.0%
3-year compound annual growth
-9.6%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $162.05M | +227.4% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $49.50M | -78.0% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $225.11M | +60.8% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $140.02M | +87.1% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $74.84M | -72.1% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $268.56M | +511.3% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $43.93M | n/a | 2021-03-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Annexon, Inc. (ANNX) | 2025-12-31 | $162.05M | +227.4% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $207.64M | +110.2% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $75.60M | +244.5% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $43.76M | +18.5% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $15.12M | -65.8% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $32.30M | -13.3% |
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $77.39M | -15.9% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.91M | -2.6% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $62.41M | +84.7% |
Compare ANNX, TNXP, CTNM, ALT side by side · Screen every company in Pharmaceutical Preparations ↗